The size of the Asia Pacific Diabetic Retinopathy Market was valued at USD 1.67 billion in 2019 and is projected to reach USD 2.44 billion by 2024, growing at a CAGR of 7.94% during the forecast period from 2019 to 2024.
Asia is predicted to show wealthy growth in the forecast period. Within the Asian region, the western pacific region accounts for a larger share of blindness due to DR when equated to South-East Asia. The major factor contributing to the increasing share of Diabetic Retinopathy among the growing economies is a huge pool of patients and increasing support and funding given by the government.
Diabetic retinopathy is considered a severe sight-threatening problem that results due to chronic diabetes. The treatment for diabetic retinopathy may require intraocular injections, anti-VEGF drugs, laser surgery or vitrectomy depending on the severity of the condition.
Rapidly expanding diabetic population coupled with increasing awareness of people regarding diabetic retinopathy is expected to drive the growth of the global diabetic retinopathy drug market in the coming years. Rising medical procedures due to the high penetration of medical insurance and rising government initiatives for the prevention of diabetes-related risks is also believed to garner the growth of the retinopathy drug market in the future.
This research report has been segmented and sub-segmented into the following categories:
Regionally, the Asia Pacific diabetic retinopathy market is expected to maintain the highest growth rate during the forecast period. The market growth is mainly attributed to the low-income population, lack of skilled professionals, and poor access to healthcare facilities in the region. With the emergence of combination therapy for diabetic macular edema, the Asia-Pacific region and emerging markets in LAMEA are supposed to provide market growth opportunities.
Emerging economies such as Japan and China in the APAC Diabetic Retinopathy Market are forecasting development due to the rising disposable income, a growing elderly population, increasing funding for diabetes research, diagnostic innovations, and large target populations. The Chinese diabetic retinopathy market is anticipated to achieve rapid growth during the outlook period. Japan is the largest market in the Asia-Pacific region, mainly due to high medical costs and increasing disposable income. Also, increased use of Lucentis is foreseen to drive market growth in the area.
Prominent companies in the APAC Diabetic Retinopathy Market profiled in the report are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug
5.1.2 Intraocular Steroid Injection
5.1.3 Laser Surgery
5.1.4 Vitrectomy
5.2 By Indication
5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)
5.2.1.1 Mild
5.2.1.2 Moderate
5.2.1.3 Severe
5.2.2 Proliferative Diabetic Retinopathy (PDR)
5.3 By End Users
5.3.1 Hospitals
5.3.2 Ophthalmic Clinics
5.3.3 Ambulatory Surgical Centers
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bayer AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Hoffmann-La Roche ltd
8.4 Regeneron Pharmaceutical Inc.
8.5 Novartis AG
8.6 Valeant Pharmaceutical International Inc.
8.7 Abbott Laboratories Inc.
8.8 Alimera Science Inc.
8.9 Ampio Pharmaceuticals Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
